Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | serine/threonine protein kinase | 0.0466 | 1 | 1 |
Loa Loa (eye worm) | TKL/MLK/LZK protein kinase | 0.0407 | 0.8685 | 0.8267 |
Brugia malayi | Protein kinase domain containing protein | 0.0407 | 0.8685 | 0.8267 |
Onchocerca volvulus | Kinase homolog | 0.0153 | 0.3018 | 0.5 |
Echinococcus granulosus | c-Jun N-terminal kinases | 0.0466 | 1 | 1 |
Loa Loa (eye worm) | STE/STE7/MEK4 protein kinase | 0.0153 | 0.3018 | 0.0796 |
Echinococcus granulosus | dual specificity mitogen activated protein | 0.0153 | 0.3018 | 0.0796 |
Loa Loa (eye worm) | hypothetical protein | 0.0405 | 0.8637 | 0.8203 |
Echinococcus granulosus | mitogen-activated protein kinase kinase kinase 9 | 0.0288 | 0.6036 | 0.4774 |
Echinococcus granulosus | mitogen activated protein kinase kinase kinase | 0.0407 | 0.8685 | 0.8267 |
Echinococcus multilocularis | dual specificity mitogen activated protein | 0.0153 | 0.3018 | 0.0796 |
Schistosoma mansoni | kinase | 0.0153 | 0.3018 | 0.3018 |
Loa Loa (eye worm) | hypothetical protein | 0.0405 | 0.8637 | 0.8203 |
Schistosoma mansoni | serine/threonine protein kinase | 0.028 | 0.5857 | 0.5857 |
Echinococcus multilocularis | mitogen activated protein kinase kinase kinase | 0.0407 | 0.8685 | 0.8267 |
Brugia malayi | Serine/threonine-protein kinase F42G10.2 | 0.0153 | 0.3018 | 0.0796 |
Schistosoma mansoni | serine/threonine protein kinase | 0.0414 | 0.8846 | 0.8846 |
Schistosoma mansoni | protein kinase | 0.0126 | 0.2414 | 0.2414 |
Loa Loa (eye worm) | CMGC/MAPK/JNK protein kinase | 0.0466 | 1 | 1 |
Echinococcus multilocularis | mitogen activated protein kinase kinase kinase | 0.0288 | 0.6036 | 0.4774 |
Echinococcus multilocularis | c Jun NH2 terminal kinase | 0.0466 | 1 | 1 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.